Ultra-rapid opiate detoxification followed by nine months of naltrexone maintenance therapy in Iran

Pharmacopsychiatry

Volumn 43, Issue 4, 2010, Pages 130-137

  Naderi Heiden, A ^a   Naderi, A ^b   Naderi, M M ^a   Rahmani Didar, F ^c   Salimi, A R ^d   Gleiss, A ^a   Kasper, S ^a   Frey, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Sadra Surgical Center   (Iran)

^c Naja Hospital   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; DIAMORPHINE; NALOXONE; NALTREXONE; OPIATE; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; CONFUSION; DEPRESSION; DRUG DETOXIFICATION; DRUG INFUSION; GENERAL ANESTHESIA; HUMAN; INTRAVENOUS DRUG ABUSE; IRAN; MAINTENANCE THERAPY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ULTRA RAPID OPIATE DETOXIFICATION; UNCONSCIOUSNESS; WITHDRAWAL SYNDROME; EPIDEMIOLOGY; FOLLOW UP; MIDDLE AGED; OPIOID-RELATED DISORDERS; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

ADULT; ANESTHESIA, GENERAL; FOLLOW-UP STUDIES; HUMANS; IRAN; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 77953900954     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0029-1242820     Document Type: Article

References (47)

1. Abnet C-C, Saadatian-Elahi M, Pourshams A et al. Reliability and Validity of opiate use self-report in a population at high risk for esophageal cancer in Golestan, Iran. Cancer Epidemiol Biomarkers Prev 2004 13 1068-1070
2. Adi Y, Juarez-Garcia A, Wang D et al. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: A systematic review and economic evaluation. Health Technol Assess 2007 11 1-85
3. Ahmadi J, Motamed F. Treatment success rate among Iranian opioid dependents. Substance use and misuse 2003 38 151-163
4. Albanese A-P, Gevirtz C, Oppenheim B et al. Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD). J Addict Dis 2000 19 11-28
5. Amato L, Davoli M, Minozzi S et al. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2005 20 CD003409
6. Ambrosio E, Martin S, Garcia-Lecumberri C et al. The neurobiology of cannabinoid dependence: Sex differences and potential interactions between cannabinoid and opioid systems. Life Sci 1999 65 687-694
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th ed Washington, DC: American Psychiatric Press 1994
8. Ashton C-H. Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999 83 637-649
9. Broers B, Giner F, Dumont P et al. Inpatient opiate detoxification in Geneva: Follow-up at 1 and 6 months. Drug and Alcohol dependence 2000 58 85-92
10. Collins E-D, Kleber H-D, Whittington R-A et al. Anesthesia-assisted vs. buprenorphine-or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA 2005 294 903-913
11. Day E, Ison J, Strang J. Inpatient versus other settings for detoxification for opioid dependence. Cochrane Database Syst Rev 2005 18 CD004580
12. Favrat B, Zimmermann G, Zullino D et al. Opioid antagonist detoxification under anaesthesia versus traditional clonidine detoxification combined with an additional week of psychosocial support: A randomised clinical trial. Drug Alcohol Depend 2006 81 109-116
13. Foster J, Brewer C, Steele T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol 2003 8 211-217
14. Gonzalez J-P, Brogden R-N. Naltrexone: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988 35 192-213
15. Gossop M, Green L, Phillips G et al. Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry 1989 154 348-353
16. Gowing L, Farrell M, Ali R et al. Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2004 18 (4) CD002024
17. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2006a 19 (2) CD002025
18. Gowing L, Ali R, White J. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev 2006b 25 (1) CD002021
19. Gowing L, Ali R, White J. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database Syst Rev 2006c 19 (2) CD002022
20. Handelsman L, Cochrane K-J, Aronson M-J et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987 13 293-308
21. Hensel M, Kox W-J. Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: A prospective study in methadone, heroin, codeine and morphine addicts. Acta Anaesthesiol Scand 2000 44 326-333
22. Herman B-H, Czechowicz D. NIDA scientific report of ultra rapid detoxification with anesthesia (UROD): Opinion of the consultants and criteria relating to evaluating the safety and efficacy of UROD. American National Institute on Drug Abuse (NIDA) Report 1996 23 1-8
23. Javier Alvarez F, Carmen del Rio M. Ultrarapid opiate detoxification: a look at what is happening in Spain. Addiction 1999 94 1239-1240
24. Karbakhsh M, Salehian Zandi N. Acute opiate overdose in Tehran: The forgotten role of opium. Addictive Behaviors 2007 32 1835-1342
25. Kaye A-D, Gevirtz C, Bosscher H-A et al. Ultrarapid opiate detoxification:a review. Can J Anaesth 2003 50 663-671
26. Kienbaum P, Thürauf N, Michel M-C et al. Profound increase in epinephrine concentration in plasma and cardiovascular stimulation after mu-opioid receptor blockade in opioid-addicted patients during barbiturate-induced anesthesia for acute detoxification. Anesthesiology 1998 88 1154-1161
27. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2000 4 CD001333
28. Kirchmayer U, Davoli M, Verster A-D et al. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction 2002 97 1241-1249
29. Kornor H, Waal H. From opioid maintenance to abstinence: a literature review. Drug Alcohol 2005 24 267-274
30. Krabbe P-F, Koning J-P, Heinen N et al. Rapid detoxification from opioid dependence under general anaesthesia versus standard methadone tapering: abstinence rates and withdrawal distress experiences. Addict Biol 2003 8 351-358
31. Loimer N, Schmid R-W, Presslich O et al. Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment. J Psychiat Res 1989 23 81-86
32. Lorenzi P, Marsili M, Boncinelli S et al. Searching for a general anaesthesia protocol from opioids. Eur J Anaesthesiol 1999 16 719-727
33. Madoz-Gúrpide A, Barbudo del Cura E, Leira Sanmartín M et al. Addiction characteristics as prognostic factors in opiate dependence treated with naltrexone. Actas Esp Psiquiatr 2004 32 199-210
34. McGregor C, Ali R, White J-M et al. A comparison of antagonist- precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. Drug Alcohol Depend 2002 68 5-14
35. McLellan A-T, Kushner H, Metzger D et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992 9 199-213
36. Minozzi S, Amato L, Vecchi S et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews 2006 Issue 1. Art. No.: CD001333. DOI: 10.1002/14651858.CD001333
37. Presslich O, Loimer N, Lenz K et al. Opiate detoxification under general anesthesia by large doses of naloxone. J Toxicol Clin Toxicol 1989 27 263-270
38. Rabinowitz J, Cohen H, Kotler M. Outcome of ultrarapid opiate detoxification combined with naltrexone maintenance and counseling. Psychiatr Serv 1998 49 831-833
39. Rabinowitz J, Cohen H, Atias S. Outcomes of naltrexone maintenance following ultra rapid opiate detoxification versus intensive inpatient detoxification. Am J Addict 2002 11 52-56
40. Satel S-L, Kosten T-R, Schuckit M-A et al. Should protracted withdrawal from drugs be included in DSM-IV? Am J Psychiatry 1993 150 695-704
41. Singh J, Basu D. Ultra-rapid opioid detoxification: current status and controversies. J Postgrad Med 2004 50 227-232 (Pubitemid 39440082)
42. Sullivan M-A, Garawi F, Bisaga A et al. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007 91 289-292
43. Teplin D, Raz B, Daiter J et al. Measurement of symptom withdrawal severity in a 24-hour period after the anesthesia-assisted rapid opiate detoxification procedure. Am J Drug Alcohol Abuse 2005 31 327-335
44. Van den Brink W, Haasen C. Evidenced-based treatment of opioid-dependent patients. Can J Psychiatry 2006 51 635-646
45. Van Dorp EL, Yassen A, Dahan A. Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf 2007 6 125-132
46. Wang WS, Chiou TJ, Hsieh RK et al. Lethal acute pulmonary edema following intravenous naloxone in a patient received unrelated bone marrow transplantation. Zhonghua Yi Xue Za Zhi (Taipei) 1997 60 219-223
47. Yamaguchi T, Hagiwara Y, Tanaka H et al. Endogenous cannabinoid 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res 2001 909 121-126